メラノーマ治療薬市場：タイプ、製品、流通チャネル別-2024年～2030年の世界予測

メラノーマ治療薬市場規模は2023年に54億米ドルと推計され、2024年には58億1,000万米ドルに達し、CAGR 8.32%で2030年には94億5,000万米ドルに達すると予測されます。

メラノーマ治療薬は、皮膚がんの一種であるメラノーマを治療するために特別に設計された一群の医薬品です。これらの薬剤は、免疫療法、標的療法、化学療法、オンコリティックウイルス療法など様々なタイプに分類されます。メラノーマの世界の有病率の増加が、治療薬の技術革新を促進しています。また、ヘルスケア分野への政府投資の拡大や償還政策の拡充が市場成長の原動力となっています。しかし、薬剤開発と治療に伴う高コストが市場成長に影響を与えています。厳しい規制政策と長い承認プロセスが、継続的な研究開発活動の妨げとなっています。さらに、副作用の軽減と高い効率性から、標的治療へのニーズが高まっており、市場の成長に大きな機会をもたらしています。

タイプ先端黒子型黒色腫および悪性黒子型黒色腫における非侵襲的治療の需要の高まり

先端黒子型黒色腫（ALM）は、黒色腫の中で最も一般的でないサブタイプであり、通常、手のひら、足の裏、爪の下に発生します。このカテゴリーの薬剤の必要性は、その診断の遅さと、目に見える警告徴候がないために治療が困難であることに起因します。悪性黒子型黒色腫（LMM）は、慢性的な日光曝露歴のある高齢者によくみられます。この分野の薬剤は、腫瘍がゆっくりと表面的に増殖する傾向があるため、腫瘍の分子および遺伝子プロファイルに焦点を当てることが多いです。結節性黒色腫（NM）はその急速で攻撃的な増殖で知られ、しばしば数ヵ月以内に皮膚の深層に浸潤します。エンドユーザーは、結節を縮小させ手術成績を改善する可能性のある即効性のある治療法を優先します。表在拡大型黒色腫（SSM）は最も一般的なタイプの黒色腫であり、通常、皮膚に広がるほくろとして現れます。SSMに対する薬剤の選択には、通常、転移に対処できる治療と並んで、予防および長期管理機能を有する薬剤が含まれます。

製品メラノーマの病勢進行と遺伝子変異を治療する次世代薬剤に対する需要の高まり

メラノーマにおける術後補助療法とは、手術などの一次治療後に、残存病変の除去や再発リスクの低減を目的として行われる治療を指します。一般的な術後補助療法には、免疫療法および標的療法が含まれます。生物化学療法は、メラノーマ患者に対する化学療法に生物学的治療を組み合わせたものです。この治療の必要性は、黒色腫が転移し、他の治療法では効果が不十分な場合に生じる。より積極的な治療法であり、病期が進行している場合に検討されることが多いです。転移性黒色腫の治療には、歴史的にダカルバジンなどの化学療法薬が使用されてきたが、現在では大部分が新しい治療法に取って代わられています。主に、他の治療法が禁忌であるか、腫瘍に作用可能な変異が認められない場合に使用されます。チェックポイント阻害薬などの免疫療法薬は、がん細胞を検出し破壊する免疫系の能力を向上させる。通常、切除不能や転移を含む進行メラノーマに使用されます。腫瘍溶解性ウイルス療法は、がん細胞に選択的に感染し破壊する遺伝子組み換えウイルスを用います。この治療法は通常、注射可能な病変を有し、病変の広がりが限定的な患者に好んで用いられます。分子標的治療薬は、がんに関連する特定の分子標的に作用するもので、BRAF V600変異のように腫瘍に同定可能な遺伝子変異を有する患者に好まれます。これらの薬剤は転移性黒色腫の治療状況を一変させました。

流通チャネル：利便性と遠隔医療サポートによるオンラインチャネルの需要増加

メラノーマ治療薬のオフライン流通チャネルには、主に病院薬局、小売薬局、クリニックが含まれます。これらの伝統的なチャネルは、広い範囲に届き、患者がアクセスしやすく、専門的な医療アドバイスや相談を直接提供できることから、医薬品流通のバックボーンとなってきました。メラノーマ治療薬のオンライン流通チャネルは、技術の進歩や消費者の嗜好の変化によって急速に成長しています。オンライン薬局やドラッグデリバリー・サービスは、処方箋の管理、リマインダー、遠隔医療相談を可能にするデジタル・プラットフォームのサポートにより、患者に在宅配達の利便性を提供しています。オフラインのチャネルでは、専門家による指導を直接受けることができ、薬にすぐにアクセスできるため、緊急に治療が必要な患者にとっては極めて重要です。逆にオンライン・チャネルは、利便性と低価格を実現し、地理的に広い患者層にリーチできます。

地域別の洞察

南北アメリカは皮膚がんの罹患率が高いため、メラノーマ治療薬の重要な市場となっています。先進的なヘルスケアインフラ、メラノーマに関する高い認知度、償還政策が、消費者の旺盛なニーズに寄与しています。米国のメラノーマ治療薬市場は、FDAによる有望な治療法の迅速承認に支えられた標的療法と免疫療法のイノベーションによって牽引されています。患者支援プログラムや保険適用が顧客の購買行動に影響を与えることも多いです。欧州のメラノーマ治療薬市場は規制が厳しく、効率的で費用対効果の高い治療が重視されています。欧州連合（EU）諸国は、黒色腫患者の増加と確立されたヘルスケアシステムの存在により、高い消費者ニーズを示しています。新しい治療法の採用は、欧州医薬品庁（EMA）の規制や新薬の価値を評価するHTA（医療技術評価）機関の影響を受けています。メラノーマ治療薬.European Unionにおける研究開発活動を支援する欧州連合のイニシアチブは、中東諸国における医療への投資を増大させています。中東諸国では、ヘルスケアへの投資が拡大し、革新的な治療に対するニーズが高まっています。アジア太平洋地域では黒色腫の患者が急増しており、中国、日本、インドなどが消費者ニーズの高まりに大きく貢献しています。APACでは、ヘルスケアとイノベーションへの投資が増加し、市場が再構築され始めています。APACのメラノーマ治療薬市場は、政府のイニシアティブと臨床試験中の強力な治療パイプラインの組み合わせから恩恵を受けています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはメラノーマ治療薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、メラノーマ治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.メラノーマ治療薬市場の市場規模および予測は？

2.メラノーマ治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.メラノーマ治療薬市場の技術動向と規制枠組みは？

4.メラノーマ治療薬市場における主要ベンダーの市場シェアは？

5.メラノーマ治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で黒色腫やその他の皮膚がんの罹患率が上昇
    • ヘルスケアに対する政府支出の増加
    • 腫瘍学分野におけるバイオシミラーの開発促進
  • 抑制要因
    • 医薬品の開発と治療にかかる高額な費用
  • 機会
    • 副作用の減少と効率性の向上による標的治療の必要性の高まり
    • 有効な薬剤の導入に向けた研究開発活動を継続
  • 課題
    • 厳格な規制方針と長い承認プロセス
• 市場セグメンテーション分析
  • タイプ：末端黒子型悪性黒色腫および悪性黒子型悪性黒色腫における非侵襲的治療法の需要増加
  • 製品：悪性黒色腫の病気の進行と遺伝子変異を治療する次世代医薬品の需要が増加
  • 流通チャネル：利便性と遠隔医療サポートによるオンラインチャネルの需要の高まり
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 メラノーマ治療薬市場：タイプ別

• 末端黒子型黒色腫
• 悪性黒子
• 結節性黒色腫
• 表面拡散型黒色腫

第7章 メラノーマ治療薬市場：製品別

• 補助療法
• 生物化学療法
• 化学療法薬
• 免疫療法薬
• 腫瘍溶解性ウイルス療法
• 標的治療薬

第8章 メラノーマ治療薬市場：流通チャネル別

• オフライン
• オンライン

第9章 南北アメリカのメラノーマ治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋のメラノーマ治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのメラノーマ治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • モデナ社とメルク社は、mRNA-4157（V940）とキイトルーダ（R）（ペンブロリズマブ）の併用により、高リスクステージIII/IV悪性黒色腫の患者における完全切除後の3年間の無再発生存率と無遠隔転移生存率がキイトルーダと比較して継続的に改善したことを発表しました。
  • サンファーマとフィロジェンのメラノーマ治療薬が第3相試験で有望な結果を示す
  • 米国食品医薬品局、ステージIIBまたはステージIICの悪性黒色腫の完全切除を受けた適格患者に対する補助療法としてオプジーボ（ニボルマブ）を承認
• 戦略分析と提言

第13章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. MELANOMA DRUG MARKET RESEARCH PROCESS
• FIGURE 2. MELANOMA DRUG MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MELANOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. MELANOMA DRUG MARKET DYNAMICS
• FIGURE 7. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. MELANOMA DRUG MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. MELANOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MELANOMA DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MELANOMA DRUG MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL MELANOMA DRUG MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL MELANOMA DRUG MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL MELANOMA DRUG MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL MELANOMA DRUG MARKET SIZE, BY BIOCHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL MELANOMA DRUG MARKET SIZE, BY BIOCHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL MELANOMA DRUG MARKET SIZE, BY DACARBAZINE (DTIC-DOME), BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL MELANOMA DRUG MARKET SIZE, BY DACARBAZINE (DTIC-DOME), BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL MELANOMA DRUG MARKET SIZE, BY TEMOZOLOMIDE (TEMODAR), BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL MELANOMA DRUG MARKET SIZE, BY TEMOZOLOMIDE (TEMODAR), BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL MELANOMA DRUG MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL MELANOMA DRUG MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL MELANOMA DRUG MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL MELANOMA DRUG MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL MELANOMA DRUG MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL MELANOMA DRUG MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL MELANOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL MELANOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL MELANOMA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL MELANOMA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. AMERICAS MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 62. AMERICAS MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 63. AMERICAS MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 64. AMERICAS MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 65. AMERICAS MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 66. AMERICAS MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 67. AMERICAS MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 68. AMERICAS MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 69. AMERICAS MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 70. AMERICAS MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 73. AMERICAS MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 74. AMERICAS MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 75. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 76. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 77. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 78. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 79. ARGENTINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 80. ARGENTINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 81. ARGENTINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 82. ARGENTINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 83. ARGENTINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 84. ARGENTINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 85. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 86. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 87. ARGENTINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 88. ARGENTINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 89. ARGENTINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 90. ARGENTINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 91. BRAZIL MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 92. BRAZIL MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 93. BRAZIL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 94. BRAZIL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 95. BRAZIL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 96. BRAZIL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 97. BRAZIL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 98. BRAZIL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 99. BRAZIL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 100. BRAZIL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 101. BRAZIL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 102. BRAZIL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 103. BRAZIL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 104. BRAZIL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 105. CANADA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 106. CANADA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 107. CANADA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 108. CANADA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 109. CANADA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 110. CANADA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 111. CANADA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 112. CANADA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 113. CANADA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 114. CANADA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 115. CANADA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 116. CANADA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 117. CANADA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 118. CANADA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 119. MEXICO MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 120. MEXICO MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 121. MEXICO MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 122. MEXICO MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 123. MEXICO MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 124. MEXICO MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 125. MEXICO MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 126. MEXICO MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 127. MEXICO MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 128. MEXICO MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 129. MEXICO MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 130. MEXICO MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 131. MEXICO MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 132. MEXICO MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 133. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 134. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 135. UNITED STATES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 136. UNITED STATES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 137. UNITED STATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 138. UNITED STATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 139. UNITED STATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 140. UNITED STATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 141. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 142. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 143. UNITED STATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 144. UNITED STATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 145. UNITED STATES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 146. UNITED STATES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 147. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 148. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 149. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 150. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 151. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 152. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 153. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 154. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 155. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 156. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 157. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 158. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 159. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 160. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 161. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 162. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 163. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 164. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 165. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 166. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 167. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 168. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 169. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 170. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 171. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 172. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 173. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 174. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 175. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 176. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 177. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 178. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 179. CHINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 180. CHINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 181. CHINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 182. CHINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 183. CHINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 184. CHINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 185. CHINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 186. CHINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 187. CHINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 188. CHINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 189. CHINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 190. CHINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 191. CHINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 192. CHINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 193. INDIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 194. INDIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 195. INDIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 196. INDIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 197. INDIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 198. INDIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 199. INDIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 200. INDIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 201. INDIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 202. INDIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 203. INDIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 204. INDIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 205. INDIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 206. INDIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 207. INDONESIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 208. INDONESIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 209. INDONESIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 210. INDONESIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 211. INDONESIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 212. INDONESIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 213. INDONESIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 214. INDONESIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 215. INDONESIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 216. INDONESIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 217. INDONESIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 218. INDONESIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 219. INDONESIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 220. INDONESIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 221. JAPAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 222. JAPAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 223. JAPAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 224. JAPAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 225. JAPAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 226. JAPAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 227. JAPAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 228. JAPAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 229. JAPAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 230. JAPAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 231. JAPAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 232. JAPAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 233. JAPAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 234. JAPAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 235. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 236. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 237. MALAYSIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 238. MALAYSIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 239. MALAYSIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 240. MALAYSIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 241. MALAYSIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 242. MALAYSIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 243. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 244. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 245. MALAYSIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 246. MALAYSIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 247. MALAYSIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 248. MALAYSIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 249. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 250. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 251. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 252. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 253. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 254. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 255. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 256. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 257. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 258. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 259. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 260. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 261. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 262. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 263. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 264. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 265. SINGAPORE MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 266. SINGAPORE MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 267. SINGAPORE MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 268. SINGAPORE MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 269. SINGAPORE MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 270. SINGAPORE MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 271. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 272. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 273. SINGAPORE MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 274. SINGAPORE MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 275. SINGAPORE MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 276. SINGAPORE MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 277. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 278. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 279. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 280. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 281. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 282. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 283. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 284. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 285. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 286. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 287. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 288. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 289. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 290. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 291. TAIWAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 292. TAIWAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 293. TAIWAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 294. TAIWAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 295. TAIWAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 296. TAIWAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 297. TAIWAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 298. TAIWAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 299. TAIWAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 300. TAIWAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 301. TAIWAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 302. TAIWAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 303. TAIWAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 304. TAIWAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 305. THAILAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 306. THAILAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 307. THAILAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 308. THAILAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 309. THAILAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 310. THAILAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 311. THAILAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 312. THAILAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 313. THAILAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 314. THAILAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 315. THAILAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 316. THAILAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 317. THAILAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 318. THAILAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 319. VIETNAM MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 320. VIETNAM MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 321. VIETNAM MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 322. VIETNAM MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 323. VIETNAM MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 324. VIETNAM MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 325. VIETNAM MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 326. VIETNAM MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 327. VIETNAM MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 328. VIETNAM MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 329. VIETNAM MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 330. VIETNAM MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 331. VIETNAM MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 332. VIETNAM MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 333. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 334. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 335. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 336. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 337. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 338. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 339. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 340. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 341. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 342. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 343. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 344. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 345. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 346. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 347. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 348. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 349. DENMARK MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 350. DENMARK MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 351. DENMARK MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 352. DENMARK MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 353. DENMARK MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 354. DENMARK MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 355. DENMARK MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 356. DENMARK MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 357. DENMARK MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
• TABLE 358. DENMARK MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
• TABLE 359. DENMARK MELANOMA DR

[194 Pages Report] The Melanoma Drug Market size was estimated at USD 5.40 billion in 2023 and expected to reach USD 5.81 billion in 2024, at a CAGR 8.32% to reach USD 9.45 billion by 2030.

Melanoma drugs are a class of pharmaceutical agents specifically designed to treat melanoma, a type of skin cancer. These drugs can be categorized into various types, including immunotherapies, targeted therapies, chemotherapy, and oncolytic virus therapy. Increasing prevalence of melanoma globally, driving innovations in therapeutics. In addition, growing government investments in the healthcare sector and the expansion of reimbursement policies drive market growth. However, the high costs associated with drug development and treatment impact the market growth. Stringent regulatory policies and lengthy approval processes create hindrances to ongoing research and development activities. Furthermore, emerging need for targeted therapy owing to reduced side effects and higher efficiency poses significant opportunities for market growth.

Type: Rising demand of non-invasive therapies across acral lentiginous melanoma and lentigo maligna melanoma

Acral Lentiginous Melanoma (ALM) is the least common subtype of melanoma, typically occurring on the palms, soles, or under the nails. The need for drugs in this category stems from its late diagnosis and the difficulty in treatment due to the lack of visible warning signs. Lentigo Maligna Melanoma (LMM) is commonly found in elderly patients with a history of chronic sun exposure. The drugs in this segment often focus on the molecular and genetic profiles of tumors since they tend to grow slowly and superficially. Nodular Melanoma (NM) is known for its rapid and aggressive growth, often invading deeper layers of the skin within months. End-users prioritize rapid-acting therapies with the potential to shrink nodules and improve surgical outcomes. Superficial Spreading Melanoma (SSM) is the most common type of melanoma, usually presenting as a spreading mole on the skin. Drug preferences for SSM typically involve medications with preventive and long-term management capabilities alongside treatments that can address metastasis.

Product: Boost in demand for next generation drugs to treat disease progression and genetic mutations in Melanoma

Adjuvant therapy in melanoma refers to treatments given after primary therapies, such as surgery, with the intent to eliminate residual disease and reduce the risk of relapse. Common adjuvant therapies include immunotherapies and targeted therapies. Biochemotherapy combines biological treatment with chemotherapy for melanoma patients. The need for this therapy arises when melanoma has spread and is not responding well to other treatments. It is a more aggressive treatment option and is often considered when the disease is in an advanced stage. Chemotherapy drugs, such as dacarbazine, have historically been used for treating metastatic melanoma but have now largely been replaced by newer therapies. The preference arises primarily when other treatment options are contraindicated or the tumor does not harbor actionable mutations. Immunotherapy drugs, such as checkpoint inhibitors, improve the immune system's ability to detect and destroy cancer cells. Their preference is typically for advanced melanoma, including unresectable and metastatic stages. Oncolytic virus therapy employs genetically modified viruses that selectively infect and destroy cancer cells. Preference for this therapy typically arises for patients with injectable lesions and limited disease spread. Targeted therapy drugs act on specific molecular targets associated with cancer and are preferred for patients with identifiable genetic mutations in their tumors, such as BRAF V600 mutations. These drugs have transformed the treatment landscape for metastatic melanoma.

Distribution Channel: Rising demand of online channel due to convenience and telehealth support

Offline distribution channels for melanoma drugs predominantly include hospital pharmacies, retail pharmacies, and clinics. These traditional channels have been the backbone of pharmaceutical distribution due to their wide reach, patient accessibility, and capability to provide in-person professional medical advice and consultation. The online distribution channel for melanoma drugs is rapidly growing, facilitated by technological advances and changing consumer preferences. Online pharmacies and drug delivery services offer patients the convenience of home delivery, often with the support of digital platforms that allow for prescription management, reminders, and telehealth consultations. Offline channels offer in-person professional guidance and immediate access to medication, which is crucial for patients in urgent need of treatment. Conversely, online channels provide convenience, lower prices, and the ability to reach a wider geographic patient base.

Regional Insights

The Americas have a significant market for melanoma drugs due to a higher incidence of skin cancer. Advanced healthcare infrastructure, high awareness regarding melanoma, and reimbursement policies contribute to robust consumer needs. In the United States, the melanoma drug market is driven by innovation in targeted therapies and immunotherapies, supported by the FDA's expedited approvals for promising treatments. Patient assistance programs and insurance coverage often influence customer purchasing behavior. Europe's melanoma drug market is highly regulated, with an emphasis on efficacious and cost-effective treatments. The European Union (EU) countries exhibit high consumer needs due to increasing melanoma cases and the presence of well-established healthcare systems. The adoption of new treatments is influenced by European Medicines Agency (EMA) regulations and HTA (Health Technology Assessment) bodies that assess the value of new medications. European Union initiatives supporting the ongoing research and development activities in melanoma drugs. Middle Eastern countries exhibit growing investment in healthcare and a rising need for innovative treatments. The Asia Pacific region is experiencing a surge in melanoma cases, with countries including China, Japan, and India contributing significantly to rising consumer needs. In APAC, increased investment in healthcare and innovation has begun to reshape the market. Melanoma drug market in APAC benefits from a combination of government initiatives and a strong pipeline of treatments in clinical trials.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Melanoma Drug Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Melanoma Drug Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Melanoma Drug Market, highlighting leading vendors and their innovative profiles. These include AB Science, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, CK Life Sciences Int'l., (Holdings) Inc., Clinigen Group PLC, Eli Lilly and Company, Enzon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Immunocore Limited, Merck KGaA, Moderna, Inc, Novartis AG, Pfizer, Inc., Philogen S.p.A., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Taj Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Melanoma Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • Acral Lentiginous Melanoma
  • Lentigo Maligna Melanoma
  • Nodular Melanoma
  • Superficial Spreading Melanoma

• Product
  • Adjuvant Therapy
  • Biochemotherapy
  • Chemotherapy Drugs
    • Dacarbazine (DTIC-Dome)
    • Temozolomide (Temodar)

• Immunotherapy Drugs
  • Checkpoint Inhibitors
  • CTLA-4 Inhibitors

• Oncolytic Virus Therapy
• Targeted Therapy Drugs
  • BRAF Inhibitors
  • MEK Inhibitors
• Distribution Channel
  • Offline
    • Hospital Pharmacies
    • Retail Pharmacies

• Online

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Melanoma Drug Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Melanoma Drug Market?

3. What are the technology trends and regulatory frameworks in the Melanoma Drug Market?

4. What is the market share of the leading vendors in the Melanoma Drug Market?

5. Which modes and strategic moves are suitable for entering the Melanoma Drug Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of melanoma and other skin cancers globally
    • 5.1.1.2. Increase in government expenditures on healthcare
    • 5.1.1.3. Elevated development of biosimilar in oncology arena
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with drug development and treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging need for targeted therapy owing to reduced side effects and higher efficiency
    • 5.1.3.2. Ongoing research and development activities to introduce effective drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory policies and lengthy approval process
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Rising demand of non-invasive therapies across acral lentiginous melanoma and lentigo maligna melanoma
  • 5.2.2. Product: Boost in demand for next generation drugs to treat disease progression and genetic mutations in Melanoma
  • 5.2.3. Distribution Channel: Rising demand of online channel due to convenience and telehealth support
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Melanoma Drug Market, by Type

• 6.1. Introduction
• 6.2. Acral Lentiginous Melanoma
• 6.3. Lentigo Maligna Melanoma
• 6.4. Nodular Melanoma
• 6.5. Superficial Spreading Melanoma

7. Melanoma Drug Market, by Product

• 7.1. Introduction
• 7.2. Adjuvant Therapy
• 7.3. Biochemotherapy
• 7.4. Chemotherapy Drugs
• 7.5. Immunotherapy Drugs
• 7.6. Oncolytic Virus Therapy
• 7.7. Targeted Therapy Drugs

8. Melanoma Drug Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Offline
• 8.3. Online

9. Americas Melanoma Drug Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Melanoma Drug Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Melanoma Drug Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years
  • 12.3.2. Sun Pharma and Philogen's Melanoma Drug Shows Promising Outcome in Phase 3 Trial
  • 12.3.3. U.S. Food and Drug Administration Approves Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
• 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio